Market Cap 4.79B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 392,700
Avg Vol 707,046
Day's Range N/A - N/A
Shares Out 71.95M
Stochastic %K 57%
Beta 2.28
Analysts Strong Sell
Price Target $77.59

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
BioTechHealthX
BioTechHealthX Dec. 6 at 9:09 AM
$KYMR Kymera Therapeutics surged 10.2% despite a wider Q3 loss of $0.90. With $978.7M in cash providing runway to 2H 2028 and analyst estimates rising 6.52%, KYMR could be positioning for a major biotech breakout ahead of key clinical milestones. https://biotechhealthx.com/biotech-news/kymera-therapeutics-kymr-jumps-10-2-in-a-month-is-wall-street-pricing-in-a-major-2026-breakout/
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:13 AM
Actionable Trade Alert for $KYMR: Market Context: $KYMR is currently trading at $66.23, showing bullish momentum as indicated by an RSI of 60.17, which suggests the stock is not overbought yet. The stock is above its 30-day moving average (MA30) of 63.1 and its 50-day moving average (MA50) of 60.95, indicating a positive trend. Directional Bias: The recent price action is strong, with the stock approaching its 60-day high of 68.8. The range between the 60-day high and low (43.74) provides a solid trading opportunity. Trade Plan: - Suggested Entry: $66.50 - Stop Loss: $63.00 (below MA30) - Take Profit Targets: 1. $68.00 (3% gain) 2. $70.00 (5.5% gain) 3. $77.50 (17% gain) With the current setup, a move to the third target offers a potential ROI of over 17%. Monitor the trade closely and adjust the stop loss as necessary to lock in profits. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:48 PM
Actionable Trade Alert for $KYMR: Market Context: $KYMR is currently trading at $66.23, showing bullish momentum as indicated by an RSI of 60.17, which suggests the stock is not overbought yet. The stock is above its 30-day moving average (MA30) of 63.1 and its 50-day moving average (MA50) of 60.95, indicating a positive trend. Directional Bias: The recent price action is strong, with the stock approaching its 60-day high of 68.8. The range between the 60-day high and low (43.74) provides a solid trading opportunity. Trade Plan: - Suggested Entry: $66.50 - Stop Loss: $63.00 (below MA30) - Take Profit Targets: 1. $68.00 (3% gain) 2. $70.00 (5.5% gain) 3. $77.50 (17% gain) With the current setup, a move to the third target offers a potential ROI of over 17%. Monitor the trade closely and adjust the stop loss as necessary to lock in profits. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 5 at 9:54 PM
$KYMR good luck to fellow longs!
1 · Reply
MikeyNJ
MikeyNJ Dec. 5 at 9:10 PM
$KYMR Data Monday before market open. I am sure it is good or they would have put it out without drawing attention to it.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 9:06 PM
$KYMR data for KT-621 any day now...
0 · Reply
cheruskian
cheruskian Nov. 29 at 5:14 AM
Annual update from the VC holding $KYMR in the portfolio https://www.youtube.com/watch?v=JrNoJe4eNIM
0 · Reply
cheruskian
cheruskian Nov. 27 at 6:25 AM
$KYMR this is currently trading at full retail price with no upward evaluation margin until any of their assets enter phase 3.
0 · Reply
JarvisFlow
JarvisFlow Nov. 26 at 6:04 PM
Truist Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 68 → 80.
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 2:16 PM
$KYMR hits 52-week high — Is there more room to run? 🚀 Shares have surged 64.1% YTD, outpacing the industry’s 17.7% gain, driven by excitement around KT-621’s clinical progress. Investor optimism around KT-621 is the key factor behind the recent surge. See if KYMR can keep up the momentum here 👉 https://www.zacks.com/stock/news/2795737/kymera-trades-near-52-week-high-time-to-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2795737-body-22521&ADID=SYND_STOCKTWITS_TWEET_2_2795737_BODY_22521
0 · Reply
Latest News on KYMR
The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 4 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY


Kymera Therapeutics Announces Proposed Public Offering

Jun 25, 2025, 4:05 PM EDT - 5 months ago

Kymera Therapeutics Announces Proposed Public Offering


Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:05 AM EDT - 5 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update


Why Kymera Therapeutics Stock Crushed it This Week

Apr 25, 2025, 6:03 PM EDT - 8 months ago

Why Kymera Therapeutics Stock Crushed it This Week


Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:48 PM EST - 10 months ago

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript


Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 1 year ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


BioTechHealthX
BioTechHealthX Dec. 6 at 9:09 AM
$KYMR Kymera Therapeutics surged 10.2% despite a wider Q3 loss of $0.90. With $978.7M in cash providing runway to 2H 2028 and analyst estimates rising 6.52%, KYMR could be positioning for a major biotech breakout ahead of key clinical milestones. https://biotechhealthx.com/biotech-news/kymera-therapeutics-kymr-jumps-10-2-in-a-month-is-wall-street-pricing-in-a-major-2026-breakout/
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:13 AM
Actionable Trade Alert for $KYMR: Market Context: $KYMR is currently trading at $66.23, showing bullish momentum as indicated by an RSI of 60.17, which suggests the stock is not overbought yet. The stock is above its 30-day moving average (MA30) of 63.1 and its 50-day moving average (MA50) of 60.95, indicating a positive trend. Directional Bias: The recent price action is strong, with the stock approaching its 60-day high of 68.8. The range between the 60-day high and low (43.74) provides a solid trading opportunity. Trade Plan: - Suggested Entry: $66.50 - Stop Loss: $63.00 (below MA30) - Take Profit Targets: 1. $68.00 (3% gain) 2. $70.00 (5.5% gain) 3. $77.50 (17% gain) With the current setup, a move to the third target offers a potential ROI of over 17%. Monitor the trade closely and adjust the stop loss as necessary to lock in profits. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:48 PM
Actionable Trade Alert for $KYMR: Market Context: $KYMR is currently trading at $66.23, showing bullish momentum as indicated by an RSI of 60.17, which suggests the stock is not overbought yet. The stock is above its 30-day moving average (MA30) of 63.1 and its 50-day moving average (MA50) of 60.95, indicating a positive trend. Directional Bias: The recent price action is strong, with the stock approaching its 60-day high of 68.8. The range between the 60-day high and low (43.74) provides a solid trading opportunity. Trade Plan: - Suggested Entry: $66.50 - Stop Loss: $63.00 (below MA30) - Take Profit Targets: 1. $68.00 (3% gain) 2. $70.00 (5.5% gain) 3. $77.50 (17% gain) With the current setup, a move to the third target offers a potential ROI of over 17%. Monitor the trade closely and adjust the stop loss as necessary to lock in profits. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 5 at 9:54 PM
$KYMR good luck to fellow longs!
1 · Reply
MikeyNJ
MikeyNJ Dec. 5 at 9:10 PM
$KYMR Data Monday before market open. I am sure it is good or they would have put it out without drawing attention to it.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 9:06 PM
$KYMR data for KT-621 any day now...
0 · Reply
cheruskian
cheruskian Nov. 29 at 5:14 AM
Annual update from the VC holding $KYMR in the portfolio https://www.youtube.com/watch?v=JrNoJe4eNIM
0 · Reply
cheruskian
cheruskian Nov. 27 at 6:25 AM
$KYMR this is currently trading at full retail price with no upward evaluation margin until any of their assets enter phase 3.
0 · Reply
JarvisFlow
JarvisFlow Nov. 26 at 6:04 PM
Truist Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 68 → 80.
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 2:16 PM
$KYMR hits 52-week high — Is there more room to run? 🚀 Shares have surged 64.1% YTD, outpacing the industry’s 17.7% gain, driven by excitement around KT-621’s clinical progress. Investor optimism around KT-621 is the key factor behind the recent surge. See if KYMR can keep up the momentum here 👉 https://www.zacks.com/stock/news/2795737/kymera-trades-near-52-week-high-time-to-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2795737-body-22521&ADID=SYND_STOCKTWITS_TWEET_2_2795737_BODY_22521
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 1:16 PM
$KYMR ripping to a 52-week high — but is this just the warm-up move? The stock is riding optimism around KT-621’s progress and the upcoming atopic dermatitis data, and that momentum is clearly getting priced in. Full breakdown on the setup 👉 https://www.zacks.com/stock/news/2795737/kymera-trades-near-52-week-high-time-to-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2795737-teaser-22519&ADID=SYND_STOCKTWITS_TWEET_2_2795737_TEASER_22519
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:28 PM
0 · Reply
biolover
biolover Nov. 21 at 12:14 AM
$VKTX today look institutions dumping everything small due to worry about no rate cut. Seems shorts didn’t do much or even covered. Only a few biotechs resisted primarily ones loaded with bio hedge funds that resisted price decline such as $TNGX qnd $KYMR
0 · Reply
justiceforb_85
justiceforb_85 Nov. 19 at 4:13 AM
$KYMR thoughts on where this goes with positive KT-621 data?
0 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 18 at 11:07 AM
$KYMR Outstanding article that hits the mark on KYMR's current state. So if you want to refresh your KYMR insights or learn about KYMR from scratch, this is a must read. https://beyondspx.com/quote/KYMR/analysis/kymera-therapeutics-unlocking-oral-biologic-like-efficacy-with-targeted-protein-degradation-nasdaq-kymr
0 · Reply
MitchOnX
MitchOnX Nov. 15 at 4:26 PM
$KYMR $KYMR Kymera Therapeutics Inc - 60 Second Analysis - November 15, 2025 ... https://youtu.be/AZs2UBde76o?si=kRuJIIfdO4hy9XPG via @YouTube
0 · Reply
biolover
biolover Nov. 15 at 3:29 PM
$VKTX bio hedge funds are a lot more in $GPCR than Viking or $MTSR It is an odd position that may reflect structure cheaper valuation. and show people are still confused about po vs Sc. $LLY attain 1 and with 11% ITT wt loss show small mole will not be a hit in obesity. This is a consumer driven market and Lilly can’t force doctors to Rx. Structure drug seems inferior to orfor from PK and early data efficacy and it is years behind it. Now bio hedge are pumping the price prior to data. Still any obesity company is cheaper than other immunology ( like $KYMR that they are pumping as well ) or rare disease companies .. but there is risk of disappointing data. .modeling show less efficacy and higher GI issues than orfor
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:12 PM
0 · Reply
Doozio
Doozio Nov. 7 at 3:11 AM
$KYMR it was always 🐒🍌🧠⏰♾️. Barring a fatch 💣. Obviously
0 · Reply
IN0V8
IN0V8 Nov. 6 at 5:27 AM
$KYMR Buy Barclays raises target price to $70 from $60 Jefferies raises target price to $73 from $64 Morgan Stanley raises target price to $73 from $70 Piper Sandler raises target price to $98 from $59 Wells Fargo raises target price to $69.X from $53
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 5:39 PM
Barclays has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Overweight with a target price of 60 → 70.
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 2:58 PM
Wells Fargo updates rating for Kymera Therapeutics ( $KYMR ) to Overweight, target set at 53 → 69.
0 · Reply